Prof. Maria Carmo-Fonseca, Institute for Molecular Medicine (IMM), University of Lisbon, Portugal
Prof. Yoseph Barash, University of Pennsylvania, Philadelphia, PA, USA
Prof. Manuel Irimia, Centre for Genomic Regulation, Barcelona, Spain
Dr. Katharina Höfer, Max Planck Institute for Terrestrial Microbiology, Marburg, Germany
Prof. Mary A. O’Connell, Central European Institute of Technology (CEITEC), Brno, Czech Republic
Dr. Martin Akerman, Envisagenics Inc. New York, USA
Board No.
1
Exploring circRNAs in cancer: Nanopore sequencing for MHC presentation insights
Tsipora Saadoun, Hebrew University of Jerusalem, Israel
2
Glycolytic metabolism plays a leading role in cancer. How to fight this reprogramming?
Dr. Giulia Toti, Sapienza University of Rome, Italy
3
Dissecting the influence of cargo in the performance of polymeric nanoformulations for mRNA delivery
Filipe Bras, University of Coimbra, Portugal
4
Development of exon editors of ABCA4 RNA in human retinal explants and non-human primate retina for the treatment of Stargardt disease
Dr. David Mauger, Ascidian Therapeutics, USA
5
Investigating the neuroprotective potential of RBM3-inducing antisense-oligonucleotides in preclinical models of neurodegenerative disorders
Dr. Tom Haltenhof, Free University of Berlin, Germany
6
Prof. Maria Carmo-Fonseca, Institute for Molecular Medicine (IMM), University of Lisbon, Portugal
Prof. Ron Weiss, Massachusetts Institute of Technology, USA
Dr. Amir Mor, RNAble, Ness Ziona, Israel
Prof. Rotem Karni, The Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Israel
Prof. Adrian R. Krainer, Cold Spring Harbor Laboratory, New York, USA
Prof. Annemieke Aartsma-Rus, Leiden University Medical Center, The Netherlands
Dr. Silvia Buonamici, Remix Therapeutics, Watertown, MA, USA
Prof. Masatoshi Hagiwara, MD & PhD, Professor & Chairman, Graduate School of Medicine, Department of Drug Discovery Medicine, Kyoto University, Japan
Prof. Zvika Granot, Faculty of Medicine, Hebrew University, Jerusalem, Israel
This panel will delve into the critical business and commercialization strategies necessary to translate the CancerRNA Consortium’s research findings into tangible medical solutions and products. We will explore the primary barriers and challenges associated with commercializing RNA-based therapeutics, with a focus on innovations in cancer treatment. Additionally, the discussion will highlight how partners within the CancerRNA Consortium are addressing these challenges to advance effective new anti-cancer therapies.
RNA-based therapeutics – commercialization strategies and challenges
Tamar Raz, CEO, Hadasit Medical Research Services and Development, Jerusalem, Israel
Maximizing research impact – Leveraging CANCERNA Scientific Results in Tech Transfer
Diana Domínguez, New Ventures Manager, Technology and Business Development Office, Centre for Genomic Regulation (CRG), Barcelona, Spain
IP on RNA Therapeutics
Miguel Duarte, Technology Transfer Officer, Institute of Molecular Medicine, University of Lisbon, Portugal
Bridging academia and industry for advanced therapies: RNAble/FutuRx accelerator case study
Dr. Amir Mor, RNAble, Ness Ziona, Israel
From bench to product – considerations to advance a molecule into commercial development
Simon Geissler, Global CMC Development, Merck Healthcare, Germany
Prof. Michelle L. Hastings, University of Michigan, Ann Arbor, MI, USA
Prof. Rotem Karni, The Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Israel
Prof. Juan Valcarcel, Centre for Genomic Regulation, Barcelona, Spain
Dr. Raul Mendez, Barcelona Institute for Research in Biomedicine, Barcelona, Spain
Prof. Juan Valcarcel, Centre for Genomic Regulation, Barcelona, Spain
Prof. Florian Heyd, Free University of Berlin, Germany
Prof. Michal Lotem, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Prof. Niels Schaft, University of Erlangen, Erlangen, Germany
Dr. Ivan Milenkovic, Centre for Genomic Regulation, Barcelona, Spain
Yuval Cohen, Hebrew University of Jerusalem, Israel
Dr. Martina Guerrero, Centre for Genomic Regulation, Barcelona, Spain
Carla Azar, Hebrew-University-Hadassah Medical School, Jerusalem, Israel
Anurag Prabhu, Hebrew University of Jerusalem, Israel
Dr. Jan Doerrie, Universitatsklinikum Erlangen, Germany
Dr. Aldema Sas-Chen, Tel Aviv University, Israel
Dr. Robert M. Martin, Institute for Molecular Medicine (IMM), University of Lisbon, Portugal
Prof. Evelien Smits, University of Antwerp, Belgium
Prof. Erez Levanon, Bar Ilan University, Ramat Gan, Israel
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!